Evidence map›Paper›PMID 37742734›Full record

ArticleJournal of vascular surgery2024

Implementing methods in the ELEGANCE registry to increase diversity in clinical research.

Eric A Secemsky, Jay Giri, Marianne Brodmann, Yann Gouëffic, Weiguo Fu, Alexandra J Greenberg-Worisek, Michael R Jaff, Lee Kirksey, Maureen P Kohi

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of vascular surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Contemporary Chronic Limb-Threatening Ischemia Care in the United States-Part 2: Designing Clinical Device Trials.Journal of the Society for Cardiovascular Angiography & Interventions · 2025
    Review
  3. Considerations for diversity, equity, and inclusion in vascular surgery research.Journal of vascular surgery cases and innovative techniques · 2025
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 4 countries.

Eric A SecemskyDepartment of Vascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: esecemsk@bidmc.harvard.edu.
Jay GiriDepartment of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA.
Marianne BrodmannDivision of Angiology, Medical University of Graz, Graz, Austria.
Yann GouëfficVascular Center, Groupe Hospitalier Paris Saint Joseph, Paris, France.
Weiguo FuDepartment of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Alexandra J Greenberg-WorisekPeripheral Interventions, Boston Scientific Corporation, Marlborough, MA.
Michael R JaffPeripheral Interventions, Boston Scientific Corporation, Marlborough, MA.
Lee KirkseyDepartment of Vascular Surgery, Cleveland Clinic, Cleveland, OH.
Maureen P KohiDepartment of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Boston Scientific (United States) · USBeth Israel Deaconess Medical Center · USCleveland Clinic · USFudan University · CNHôpital Paris Saint-Joseph · FRMedical University of Graz · ATUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · US

Funding

Shared Decision-Making to Improve the Health Status of Patients with Claudication: Developing and Implementing Strategies to Individualize Treatment DecisionsK23HL150290 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SECEMSKY, ERIC ALEXANDER · 2020 to 2024
$851k
NHLBI NIH HHS K23 HL150290
6 · The paper itself

Abstract

objectiveWomen and underrepresented minorities (URMs) who are at an increased risk of presenting with severe peripheral artery disease (PAD) and have different responses to treatment compared with non-Hispanic White males yet are underrepresented in PAD research.

methodsELEGANCE is a global, prospective, multi-center, post-market registry of PAD patients treated with drug-eluting device that aims to enroll at least 40% women and 40% URMs. The study design incorporates strategies to increase enrollment of women and URMs. Inclusion criteria are age ≥18 years and treatment with any commercially available Boston Scientific Corporation drug-eluting device marketed for peripheral vasculature lesions; exclusion criterion is life expectancy <1 year.

resultsOf 750 patients currently enrolled (951 lesions) across 39 sites, 324 (43.2%) are female and 350 (47.3%) are URMs (21.6% Black, 11.2% Asian, 8.5% Hispanic/Latino, and 5.3% other). Rutherford classification is distributed differently between sexes (P = .019). Treatment indication differs among race/ethnicity groups (P = .003). Chronic limb-threatening ischemia was higher for Black (38.3%) and Hispanic/Latino (28.1%) patients compared with non-Hispanic White (21.8%) and Asian patients (21.4%). De-novo stenosis was higher in Asian patients (92.3%) compared with Black, non-Hispanic White, and Hispanic/Latino patients (72.2%, 68.7%, and 77.8%, respectively; P < .001). Mean lesion length was longest for Black patients (162.7 mm), then non-Hispanic White (135.2 mm), Asian (134.8 mm), and Hispanic/Latino patients (128.1 mm; P = .008).

conclusionsAnalyses of data from the ELEGANCE registry show that differences exist in baseline disease characteristics by sex and race/ethnicity; these may be the result of other underlying factors, including time to diagnosis, burden of undermanaged comorbidities, and access to care.

Indexed as

Drug-Eluting StentsEthnicityPatient SelectionPeripheral Arterial DiseaseRacial GroupsAsianBlack or African AmericanFemaleHispanic or LatinoHumansMaleProduct Surveillance, PostmarketingProspective StudiesRegistriesWhiteClinical trialsHealth disparitiesHealth equityPatient engagementPatient recruitmentPeripheral artery disease

Identifiers

PMID37742734
PMCPMC12698378
OpenAlexW4386946117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.